Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00694057 · ClinicalTrials.gov registry record · Phase 2
Safety, Tolerance and Activity of HE3286 in Patients With Type 2 Diabetes Mellitus
A Phase 2 study, sponsored by Harbor Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 164
- Enrollment target
NCT00694057 is a Phase 2 study that has completed, run by Harbor Therapeutics. The registered enrollment target is 164 participants.
The verdict
NCT00694057, a Phase 2 study, has completed, sponsored by Harbor Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 164 participants
- Enrollment target
Study Summary
This is a phase II, double-blind, randomized, placebo-controlled study of the safety, tolerance and activity of HE3286 in patients with type 2 diabetes mellitus. Patients receiving stable metformin or who are drug-naive will receive study treatment (HE3286 or placebo) for a treatment period of 12-weeks.
Interventions
- DRUG Placebo
- DRUG HE3286
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 164 participants |
| Start Date | 2008-06 |
| Est. Completion | 2010-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00694057
The ClinicalTrials.gov registry entry for NCT00694057 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 164 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Harbor Therapeutics, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00694057 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00694057 about?
NCT00694057 is a clinical study titled "Safety, Tolerance and Activity of HE3286 in Patients With Type 2 Diabetes Mellitus". This is a phase II, double-blind, randomized, placebo-controlled study of the safety, tolerance and activity of HE3286 in patients with type 2 diabetes mellitus. Patients receiving stable metformin or who are drug-naive will receive study treatment (HE3286 or placebo) for a treatment period of 12-we...
What is the current status of trial NCT00694057?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 164 participants. The study started on 2008-06. Estimated completion is 2010-01.
What interventions are being tested in trial NCT00694057?
The interventions under investigation include: Placebo (DRUG), HE3286 (DRUG).
Who is sponsoring clinical trial NCT00694057?
This trial is sponsored by Harbor Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.